Clinical Experience with Fludarabine and its Immunosuppressive Effects in Pretreated Chronic Lymphocytic Leukemias and Low-Grade Lymphomas

References

• Lennert K. Malignant lymphomas. Springer Verlag, Berlin 1978; 106–152
   Google Scholar
• Rabinowe S.N., Soiffer R.J., Gribben J.G., Daley H., Freedman A.S., Daley J., Pesek K., Neuberg D., Pinkus G., Leavitt P.R. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1903; 82: 1366–1376
   Google Scholar
• Keating M.J., Kantarjian H., Talpaz M., Redman J., Koller C., Barlogie B., Velasquez W., Plinkett W., Freireich E.J., McCredie K.B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–24
   PubMed Web of Science ®Google Scholar
• Cheson B.D. New antimetabolites in the treatment of human malignancies. Sem. Oncol. 1989; 19: 695–706
   Google Scholar
• Keating M.J., O'Brien S., Kantarjian H., Robertson L.B., Koller C., Beran M., Estey E. Nucleoside analogues in treatment of chronic lymphocytic leukemia. Leuk. Lymph. 1993; 10: 139–145, suppl
   PubMedGoogle Scholar
• Khouri I.F., Keating M.J., Vriesendorp H.M., Reading C.L., Przepiorka D., Huh Y.O., Anderson B.S., van Besien K.W., Mehra R.C., Giralt S.A., Ippoliti C., Marshall M., Thomas M.W., O'Brien S., Robertson L.E., Deisseroth A.B, Champlin R.E. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J. Clin. Oncol. 1994; 4: 748–758
   Google Scholar
• Knospe W.H., Loeb V., Huguley C.M. Bi-weeklychlo-rambucil treatment of chronic lymphocytic leukemia. Cancer 1974; 31: 502–508
   Google Scholar
• Raphael B., Andersen J.W., Silber R., Oken M., Moore D., Bennel J., Bonner H., Hahn R., Knospe W.H., Mazza J., Glick J. Comparison of chlorambucile and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: Long-term follow-up of an Eastern Cooperative Oncology Group randomized trial. J. Clin. Oncol. 1991; 9: 770–777
   PubMed Web of Science ®Google Scholar
• French Cooperative Group on Chronic lymphocytic leukemia., Effectiveness of “CHOP” regimen in advanced chronic lymphocytic leukemia. Lancet 1986; 1: 1346–1349
   PubMed Web of Science ®Google Scholar
• Montserrat E., Alcala A., Parody R., Domingo A., Garcia-Conde J., Bueno J., Ferran C., Sanz M.A., Giralt M., Ruhio D., Anton I., Estape J., Rozman C. Treatment of chronic lymphocytic leukemia in advanced stages. Cancer 1985; 56: 2369–2375
   PubMed Web of Science ®Google Scholar
• Binet J.L. When and how to treat elderly patients with chronic lymphocytic leukemia (C.L.L.)? The French Cooperative Group on C.L.L. Hematol. Oncol. 1993; 11: 38, Suppl. 1
   PubMedGoogle Scholar
• Hickiali T., Serafinowski P., Cunningham D., Oza A., Dorland E., Judson I., Millar B.C., Lister T.A., Roldan A. 2′-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br. J. Cancer 1993; 67: 139–143
   PubMed Web of Science ®Google Scholar
• Piro L.D., Carrera C.J., Beutler E., Carson D.A. 2′-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069–1073
   PubMed Web of Science ®Google Scholar
• Kedman J.K., Cabanillas F., Velasquez W.S., McLaughin P., Hagemeister F.B., Swan F., Rodriguez M.A., Plunkett W.K., Keating M.J. Phase II trial of fludarabine phophate in lymphoma: An effective new agent in low-grade lymphoma. J. Clin. Oncol. 1992; 10: 790–794
   PubMed Web of Science ®Google Scholar
• Whelm J.S., Ganjoo R., Johnson P.W., Rohatiner A.Z., Lister T.A. Treatment of low grade non-Hodgkin's lymphomas with fludarabine. Leuk. Lymph. 1993; 10: 35–37, Suppl
   Google Scholar
• Fenchel K., Wijermans P., Mitrou P.S., Hoelzer D., Bergmann L. Fludarabine is an effective agent in immunocytic lymphoma. Onkologie. 1994; 17: 508–513
   Web of Science ®Google Scholar
• Keating M.J., Kantarjian H., O'Brien S., Koller C., Talpaz M., Schachner J., Childs C.C., Freireich E.J., McCredie K.B. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 4449
   Google Scholar
• Bergmann L., Fenchel K., Jahn B., Mitrou P.S., Hoelzer D. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann. Oncol. 1993; 4: 371–375
   PubMed Web of Science ®Google Scholar
• Ross S.R., McTavish D., Faulds D. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs 1993; 45: 737–759
   PubMed Web of Science ®Google Scholar
• Spriggs D.R., Stopa E., Mayer R.J., Schoene W., Kufe D.W. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res. 1986; 46: 5953–5958
   PubMed Web of Science ®Google Scholar
• Harvey W.H., Von Fleming T.R., Hoff D.D., Katterhagen J.G., Coltman C.A., Jr. Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study. Cancer Treatm. Rep. 1987; 71: 1319–1320
   PubMedGoogle Scholar
• Harvey W.H., Fleming T.R., Beltran G., Saiers J.H., von Oishi N., Hoff D.D. Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group Study. Cancer Treatm. Rep. 1987; 71: 1111–1112
   PubMedGoogle Scholar
• Hurst P.G., Habib M.P., Garewal H., Bluestein M., Paquin M., Greenberg B.R. Pulmonary toxicity associated with fludarabine monophosphate. Investig. New Drugs 1987; 5: 207–210
   PubMed Web of Science ®Google Scholar
• Keating M.J., O'Brien S., Kantarjian H., Plunkett W., Estey E., Koller C., Beran M., Freireich E.J. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878–2884
   PubMed Web of Science ®Google Scholar
• Chun H.G., Leyland-Jones El.R., Caryk S.M., Hoth D.F. Central nervous system toxicity of fludarabine phosphate. Cancer Treatm. Rep. 1986; 70: 1225–1228
   PubMedGoogle Scholar
• Merkel D.E., Griffin N.L., Kagan-Hallet K., VonHoff D.D. Central nervous toxicity with fludarabine. Cancer Treatment Report, 70 1986; 1449–1450
   Google Scholar
• Cohen R.B., Abdallah J.M., Gray J.R., Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann. Int. Med. 1993; 118: 114–116
   PubMed Web of Science ®Google Scholar
• Lennert K., Feller A.C. Histopathologie der non-Hodgkin Lymphome. Springer Verlag., Berlin 1990; 121–162
   Google Scholar
• Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F., Thomas M., Tchernia G., Jacquillat C., Boivin P., Lesty C., Duault M.T., Monconduit M., Belabbes S., Gremly F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–201
   PubMed Web of Science ®Google Scholar
• Carbone P.P., Kaplan H.S., Musshoff K., Smithen D.W., Tubiana M. Report of the committee on Hodgkin's disease staging. Cancer Res. 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Kantarjian H.M., Alexanian R., Koller C.A., Kurzrock R., Keating M.J. Fludarabine therapy in macroglobulinemic lymphoma. Blood 1990; 75: 1928–1931
   PubMed Web of Science ®Google Scholar
• Dimopoulos M.A., O'Brien S., Kantarjian H., Pierce S., Delasalle K., Barlogie B., Alexanian R., Keating M.J. Fludarabine therapy in Waldenström's macroglobulinemia. Am. J. Med. 1993a; 95: 49–52
   PubMed Web of Science ®Google Scholar
• Dimopoulos M.A., Kantarjian H., Estey E., O'Brien S., Delasalle K., Keating M.J., Freireich E.J., Alexanian R. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann. Int. Med. 1993b; 118: 195–198
   PubMed Web of Science ®Google Scholar
• Frame J.N., Dahut W.L., Crowley S. Fludarabine and acute tumor lysis in chronic lymphocytic leukemia [letter]. N. Engl. J. Med. 1992; 327: 1396–1397
   PubMed Web of Science ®Google Scholar
• Schilling P.J., Vadhan-Raj S. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 1990; 323: 833–834
   PubMed Web of Science ®Google Scholar
• VonHoff D.D., Dahlberg S., Hartstock R.J., Eyre H.J. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Goup study. J. Natl. Cancer Inst. 1990; 82: 1353–1355
   PubMed Web of Science ®Google Scholar
• Anaissie E., Kontoyiannis D.P., Kantarjian H., Eking L., Robertson L.E., Keating M. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann. Int. Med. 1992; 117: 466–469
   PubMed Web of Science ®Google Scholar
• Wijermans P.W., Gerrits W.B., Haak H.L. Severe immunodeficiency in patients treated with fludarabine monophosphate. Europ, J. Haematol. 1993; 50: 292–296
   PubMed Web of Science ®Google Scholar
• Spielberger R.T., Stock W., Larson R.A. Listeriosis after 2-chlorodeoxyadenosine treatment [letter]. N. Engl. J. Med. 1993; 328: 813–814
   PubMed Web of Science ®Google Scholar
• Betticher D.C., von Fey M.F., Rohr A.T., Jemzer H., Gratwohl A. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic lymphocytic acute leukaemias. Ann. Oncol. 1994; 5: 57–64
   PubMed Web of Science ®Google Scholar
• Lauria F., Rondelli D., Raspadori D., Benfenati D., Tura S. 2-Rapid restoration of natural killer cell activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy cell leukemia. Eur. J. Haematol. 1994; 52: 16–20
   PubMed Web of Science ®Google Scholar
• Binet J.L., Chastang C., Chevret S., Dighiero G., Maloum K., Travade P. Comparison of Fludarabine, CAP and CHOP in advanced previously untreated chronic lymphocytic leukemia. Preliminary results of a randomized clinical trial. Blood 1993b; 82: 140, Suppl. 1
   Google Scholar
• La Ruskin J., Riviere M. Low-dose cotrimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 1991; 337: 468–471
   PubMed Web of Science ®Google Scholar
• Elias L., Stock-Novak G., Head D.R., Grever M.R., Weick J.K., Chapman R.A., Godwin J.E., Metz E.N., Appelbaum F.R. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Leukemia 1993; 7: 361–365
   PubMed Web of Science ®Google Scholar
• Robertson L.E., Keating M.J.K. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions. Cancer Treatm. Res. 1993; 64: 105–119
   PubMedGoogle Scholar